Dr Thomson qualified from Oxford in 2004, with a First Class honours degree. He was awarded a Doctor of Medicine (MD) research degree from Manchester in 2015, with clinical research in proton therapy at the University of Pennsylvania. He also completed a Postgraduate Certificate in Medical Education with Distinction (Edge Hill, 2014). Dr Thomson was appointed Consultant Clinical Oncologist at The Christie (2015) and Honorary Senior Lecturer at The University of Manchester, specialising in head and neck cancer.
As the Head and Neck Clinical Lead for Greater Manchester Cancer, Dr Thomson is passionate about improving the survival outcomes and long-term quality of life for patients. He is Chief Investigator for the UK phase 3 NIMRAD trial (hypoxia modification using nimorazole with radiotherapy for head and neck cancer) and Chief Investigator for the UK phase 3 TORPEdO trial (proton beam therapy to reduce side effects for oropharyngeal cancer). Dr Thomson is a member of the National Proton Panel and was clinical lead for NHSE policy development for proton beam therapy in head and neck cancer. He is also clinical lead for development and implementation of electronic patient reported outcomes in head and neck cancer at The Christie.